Treatment with antivirals improves liver outcomes in hepatitis C
A new study from Korea University suggests that treatment with direct-acting antivirals (DAAs) improves liver disease-related clinical outcomes in patients with chronic hepatitis C virus (HCV) infection and reduces liver fibrosis-based disease burden.
In recent years, DAAs that block replication of HCV have dramatically transformed the treatment of the disease, with around 90% effective anti-viral response rates. However, it is unclear whether DAAs impact the severity of disease burden caused by liver fibrosis.
Associate Professor Seungbong Han from the Department of Biostatistics, Korea University College of Medicine, South Korea collaborated with his colleagues across multiple centres in South Korea to evaluate the impact of DAAs on the fibrotic disease burden in patients with chronic HCV infection.
Associate Professor Han says: “For individuals, early detection and effective treatment would mean fewer complications, better health outcomes, and enhanced quality of life. Successful strategies could serve as models for other countries with high hepatitis C prevalence, leading to global improvement in hepatitis C management.”
The team collected medical records of 11,725 patients with HCV infection from 29 institutions in South Korea. They compared individual participant data from 3,261 untreated to 8,464 patients treated with DAAs, for a follow-up period of 27.5 months.
They observed that DAA treatment reduced fibrotic disease burden and lowered the risk of disease progression to cancer or cirrhosis, increasing life expectancy. The differences were most prominent in age groups 40–60 years.
One of the limitations of this study is the reliance on non-invasive tests for measuring liver fibrosis.
“Our study can help improve public health, healthcare systems, and individual lives by encouraging the development of early intervention and effective treatment strategies for HCV infection,” concluded Associate Professor Han.
Diana Spencer, Senior Digital Content Editor, DDW
